



February 19, 2020

Patented Medicine Prices Review Board  
(PMPRB.Consultations.CEPMB@pmprb-cepmb.gc.ca)

Thank you for the notification regarding the launch of the Patented Medicine Prices Review Board (PMPRB) consultations on new draft pricing guidelines. The Honourable Jim Reiter, Minister of Health, has asked that I respond.

I appreciate the links to the consultation materials, and information regarding the consultation process. I would also like to thank you for the in-person meeting that was held on December 5, 2019, where representatives of the PMPRB presented information regarding the modernization of Canada's pricing framework for patented drugs. Drug Plan and Extended Benefits staff were in attendance along with representatives of our Deputy Minister's Office and the Saskatchewan Cancer Agency.

A representative from the Drug Plan and Extended Benefits Branch attended the PMPRB Health Partners Working Group meeting in January. This meeting was very informative, and we appreciated the opportunity to ask questions and discuss the proposed guidelines in more depth.

Saskatchewan continues to support the important work of the PMPRB to protect Canadians and public drug plans from excessive prices for patented medicines. I look forward to learning more about the outcome of the consultations and the modernization process that is underway.

Sincerely,

A handwritten signature in blue ink, appearing to read "Nick Doulias".

Nick Doulias  
Executive Director

cc: Honourable Jim Reiter, Minister of Health (19-706)

---